» Articles » PMID: 8558020

Requirement for Phosphatidylinositol 3'-kinase to Protect Hemopoietic Progenitors Against Apoptosis Depends Upon the Extracellular Survival Factor

Overview
Journal J Immunol
Date 1996 Feb 1
PMID 8558020
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hemopoietic growth factors promote survival of progenitor cells by preventing their apoptotic death. Recently, phosphatidylinositol 3'-kinase (PI 3-kinase) has been shown to be integral in the pathway by which insulin and nerve growth factor prevent apoptosis. In this work, we show that IL-3-dependent FDCP-1/Mac-1 murine hemopoietic progenitors express receptors for another growth factor, insulin-like growth factor-I (IGF-I), and that both IL-3 and IGF-I stimulate PI 3-kinase activity. We then demonstrate that IGF-I shares with IL-3 the properties of significantly promoting proliferation and enhancing survival of myeloid progenitor cells at concentrations as low as 3 ng/ml. IL-3 and IGF-I efficiently promote cell survival in the presence of inhibitors of either RNA synthesis (actinomycin D) or mitosis (mitomycin C), suggesting that both ligands promote survival by a process that is largely independent of RNA synthesis. To determine whether PI 3-kinase mediates IL-3- and IGF-I-induced inhibition of apoptosis, FDCP-1/Mac-1 cells were incubated with the PI 3-kinase inhibitor, wortmannin. While wortmannin inhibited both basal and IGF-I- and IL-3-induced PI 3-kinase enzyme activity, it did not affect the ability of IL-3 to protect FDCP-1/Mac-1 cells from apoptosis, even though it abrogated the IGF-I-induced inhibition of apoptosis. These data demonstrate that even though activation of PI 3-kinase is a pleiotropic feature of both IL-3 and IGF-I receptors in myeloid progenitors, prevention of apoptosis by IL-3 but not IGF-I is independent of PI 3-kinase. Survival of hemopoietic progenitors is therefore maintained by at least two different intracellular signaling pathways, one requiring PI 3-kinase and one that does not.

Citing Articles

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.

Amarante-Mendes G, Rana A, Datoguia T, Hamerschlak N, Brumatti G Pharmaceutics. 2022; 14(1).

PMID: 35057108 PMC: 8780254. DOI: 10.3390/pharmaceutics14010215.


CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.

Brunner-Weinzierl M, Rudd C Front Immunol. 2018; 9:2737.

PMID: 30542345 PMC: 6277866. DOI: 10.3389/fimmu.2018.02737.


Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.

Zhou D, Deoliveira D, Kang Y, Choi S, Li Z, Chao N Int J Radiat Oncol Biol Phys. 2012; 85(4):1141-8.

PMID: 23021438 PMC: 3562560. DOI: 10.1016/j.ijrobp.2012.08.014.


The inhibitory effect of dibutyryl cyclic AMP on docosahexaenoic acid-induced apoptosis in HL-60 cells through activation of the phosphatidylinositol-3 kinase pathway.

Miura Y, Murata Y, Utsumi K, Takahata K, Tada M, Otsuki T Environ Health Prev Med. 2011; 10(4):184-9.

PMID: 21432138 PMC: 2723312. DOI: 10.1007/BF02897709.


Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates.

Chen B, Deoliveira D, Spasojevic I, Sempowski G, Jiang C, Owzar K PLoS One. 2010; 5(6):e11056.

PMID: 20585403 PMC: 2886847. DOI: 10.1371/journal.pone.0011056.